HK Stock MarketDetailed Quotes

02359 WUXI APPTEC

Watchlist
  • 57.100
  • -0.850-1.47%
Not Open Dec 12 16:08 CST
164.90BMarket Cap16.26P/E (TTM)

About WUXI APPTEC Company

The company provides global partners with a full range of new drug development and production services, covering all aspects of new drug research and development, so that anyone and any company can realize their dream of innovation through our enabling platform. We are committed to lowering the R&D threshold, improving R&D efficiency, promoting the early introduction of more new drugs and good drugs, and benefiting patients around the world through integrated and open capabilities and technology platforms. The company's main business can be divided into five major segments: chemical business (wuxiTesting), biology business (wuxiBiology), cell and gene therapy CTDMO business (wuxiTU), and domestic new drug development service department (wuxiDSU). The scope of services covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions. Company honors include Baihua Association's “Enterprise of the Year Award”, Sina Pharmaceuticals's “Most Influential Enterprise in China's Pharmaceutical Industry”, and “China's 100 Model Employers” for four consecutive years.

Company Profile

Symbol02359
Company NameWUXI APPTEC
ISINCNE100003F19
Listing DateDec 13, 2018
Issue Price68.00
Shares Offered116.47M share(s)
FoundedDec 1, 2000
Registered AddressChina
Chairmange li
Secretaryyuefenzhangyuanzhou zhang
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficeNo. 5 Mashan Bridge, Binhu District, Wuxi City, Jiangsu Province
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees38134
MarketHong Kong motherboard
Phone86-21-20663091
Fax86-21-50463093
Emailir@wuxiapptec.com
BusinessDevelopment, research and approval of research and development of new drugs, pharmaceutical intermediates and fine chemical products (excluding hazardous chemicals); pharmaceutical technology, biotechnology, combinatorial chemistry, organic chemistry, medical technology, testing technology, computer technology technology development, technology transfer, technical services and technical consulting; wholesale of first-class medical devices and pharmaceuticals, sales of mechanical equipment and spare parts; self-employment and agency of import and export business of various types of products and technologies (excluding products and technologies operated by state-restricted enterprises or prohibited from being imported and exported); enterprise management consulting, pharmaceutical information consulting, health consulting (excluding medical and treatment activities, psychological counseling) ; Housing rental; conference and exhibition services; foreign investment using own capital. (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments) (Final approval for industry and commerce)

Company Executives

  • Name
  • Position
  • Salary
  • ge li
  • Chairman, Executive Director, Contact the CEO, Chairman of the Strategy Committee, Nomination Committee Members
  • 61.93M
  • minzhang chen
  • Executive Director, Co-CEO
  • 24.93M
  • zhengguo hu
  • Vice Chairman, Executive Director, Chief Investment Officer, Strategy Committee Members, Authorized Representative
  • 17.75M
  • qing yang
  • Executive Director, Co-CEO
  • 17.52M
  • chaohui zhang
  • VP, Executive Director, Chief Operating Officer
  • 12.43M
  • xiaomeng tong
  • Non-executive Directors, Strategy Committee Members
  • --
  • yibing wu
  • Non-executive Directors, Strategy Committee Members
  • --
  • shaohua lu
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • 233.00K
  • wei yu
  • Independent Non-Executive Director, Strategy Committee Members, Audit Committee Members
  • 233.00K
  • xin zhang
  • Independent Non-Executive Director, Audit Committee Members, Member of the Remuneration and Assessment Committee
  • 233.00K
  • zhiling zhan
  • Independent Non-Executive Director, Chairman of the Remuneration and Assessment Committee, Nomination Committee Members
  • 233.00K
  • dai feng
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
  • 400.00K
  • liang he
  • Chairman of the Supervisory Board, Shareholders' Representatives and Supervisors
  • --
  • baiyang wu
  • Auditors
  • --
  • minfang zhu
  • Employee Representative Supervisor
  • --
  • ming shi
  • Chief Financial Officer
  • --
  • shuhui chen
  • Company Advisors
  • --
  • yuanzhou zhang
  • Joint Company Secretary, Authorized Representative
  • --
  • yuefen zhang
  • Joint Company Secretary, Authorized Representative
  • --
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks

Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.